title: The Impact of a Topical Sexual Enhancement Cream on the Female Sexual Response and Its Relationship to Clitoral Blood Flow.
abstract: OBJECTIVE
  The aim of this investigation was to determine, through two Investigational Review Board (IRB)-approved studies, if a new topical vasodilating cream (NTVC; Life Science Enhancement Corporation, Pittsburgh PA) could improve female sexual response. Study I subjectively evaluated sexual female response as accessed by a modification of the Female Intervention Efficacy Index (FIEI). FIEI was developed at the University of California as an immediate outcome measure of medical intervention to treat female sexual dysfunction.1 In Study II, 10 randomly selected positive responders from Study I were subsequently analyzed objectively with clitoral plethysmography in order to determine the effect of the NTVC and placebo on blood flow.2 RESULTS: In the subjective Study I (81 patients ranging in age from 18 to 63), a positive response trend for the NTVC was demonstrated compared to the placebo. In the objective Study II, 10 randomly selected patients who responded positive in Study I were objectively evaluated for response of increased blood flow in the clitoris after application of both the NTVC and placebo. The clitoral blood flow was shown to have increased with statistical significance for the NTVC in all 10 patients compared to the placebo, with the NTVC exhibiting an average 69% increase in clitoral blood flow.
  
  
  CONCLUSIONS
  The female sexual response is complex. In the subjective Study I, the NTVC demonstrated positive trends for enhanced lubrication, genital sensation, intercourse, and overall sexual experience. In the objective Study II, 10 of the positive subjective responders from Study I were randomly selected to evaluate their response to the NTVC compared to the placebo. This was done via Doppler plethysmography (DP). All 10 patients demonstrated a statistically significant response rate for increase in clitoral blood flow using the NTVC compared to the placebo, with an average blood flow increase of 69%. This portion of the investigation demonstrates a significant positive end organ response to the NTVC. The positive subjective trends combined with the significant and substantial increase in clitoral blood flow may result in enhanced female sexual satisfaction.
authors.affiliation: Obstetrics and Gynecology Department, Female Pelvic Medicine and Reconstructive Surgery, West Penn Allegheny Health System, Pittsburgh, Pennsylvania.
authors.forename: Michael
authors.initials: M
authors.lastname: Pelekanos
authors.affiliation: University of Pittsburgh Medical Center, Mercy Division, Clinical Professor of Plastic Surgery, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
authors.forename: Guy M
authors.initials: GM
authors.lastname: Stofman
authors.affiliation: University of Pittsburgh School of Medicine, Private Practice, Dermatology, Pittsburgh, Pennsylvania.
authors.forename: Neil
authors.initials: N
authors.lastname: Niren
mesh_terms: D000293:Adolescent; D000328:Adult; D002987:Clitoris / Q000098:blood supply* / Q000502:physiology; D005260:Female; D006801:Humans; D008875:Middle Aged; D012039:Regional Blood Flow; D012725:Sexual Behavior; D014665:Vasodilator Agents / Q000627:therapeutic use*; D055815:Young Adult
chemical_list: D014665:Vasodilator Agents